The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions.
Yuzhuo Wang, Joshua Scurll, Itzel Astiazar��n Rasc��n, Cassandra Cui, Yuchao Ni, Ace Mingchen Shi, Priyadarsini Gangadharannambiar, Yu Wang, Shusuke Akamatsu, Himisha Beltran, Michael Cox, Francesco Crea, Mads Daugaard, Xuesen Dong, Michael Haffner, Hansen He, Elena Jachetti, Natasha Kyprianou, Benyi Li, Christopher E Ong, David S Rickman, Triparna Sen, Helen He Zhu, Amina Zoubeidi, Martin E Gleave
Author Information
Yuzhuo Wang: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada. ORCID
Joshua Scurll: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
Itzel Astiazar��n Rasc��n: BC Cancer Research Institute, BC Cancer, Vancouver, BC, V5Z 1L3, Canada.
Cassandra Cui: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
Yuchao Ni: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
Ace Mingchen Shi: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
Priyadarsini Gangadharannambiar: Open University, School of Life Health & Chemical Sciences, Milton Keynes, MK7 6AA, UK.
Yu Wang: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
Shusuke Akamatsu: Department of Urology, Nagoya University Graduate School of Medicine, Aichi, 466-8550, Japan.
Himisha Beltran: Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Michael Cox: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
Francesco Crea: Open University, School of Life Health & Chemical Sciences, Milton Keynes, MK7 6AA, UK. ORCID
Mads Daugaard: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
Xuesen Dong: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
Michael Haffner: Divisions of Human Biology & Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Hansen He: Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2C1, Canada.
Elena Jachetti: Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy.
Natasha Kyprianou: Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Benyi Li: Department of Urology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Christopher E Ong: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
David S Rickman: Department of Pathology & Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Triparna Sen: Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Helen He Zhu: State Key Laboratory of Oncogenes & Related Genes, Renji-Med-X Stem Cell Research Center, Department of Urology, Ren Ji Hospital, School of Medicine & School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200127, China.
Amina Zoubeidi: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
Martin E Gleave: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
neuroendocrine prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer (PCa), emerging from advanced treatments and characterized by loss of androgen receptor (AR) signaling and neuroendocrine features, leading to rapid progression and treatment resistance. The third symposium on treatment-induced NEPC, held from 21 to 23 June 2024, at Harrison Hot Springs Resort, BC, Canada, united leading global researchers and clinicians. Sponsored by the Vancouver Prostate Centre (VPC), Canadian Institute of Health Research, prostate cancer Foundation Canada and Pharma Planter Inc, the event focused on the latest NEPC research and innovative treatment strategies. Co-chaired by Drs. Yuzhuo Wang and Martin Gleave, the symposium featured sessions on NEPC's historical context, molecular pathways, epigenetic regulation and the role of the tumor microenvironment and metabolism in its progression. Keynotes from experts like Dr. Himisha Beltran and Dr. Martin Gleave highlighted the complexity of NEPC. The Emerging Talent session showcased new research, pointing to the future of NEPC treatment. The symposium concluded with a consensus on the need for early detection, targeted therapies and personalized medicine to effectively combat NEPC, emphasizing the importance of global collaboration in advancing NEPC understanding and treatment.
